

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6343905

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
ANNA BUNIN	02/05/2019
LAWRENCE G. IBEN	01/31/2019
DOUGLAS MANION	02/05/2019
DAVID ADAM SPIEGEL	02/05/2019
MATTHEW ERNEST WELSCH	01/31/2019
RECEIVING PARTY DATA	
Name:	KLEO PHARMACEUTICALS, INC.
Street Address:	25 SCIENCE PARK, SUITE 2D
Internal Address:	150 MUNSON STREET
City:	NEW HAVEN
State/Country:	CONNECTICUT
Postal Code:	06511
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16960534
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Email:	patentdocket@choate.com
Correspondent Name:	CHOATE, HALL AND STEWART LLP
Address Line 1:	TWO INTERNATIONAL PLACE
Address Line 4:	BOSTON, MASSACHUSETTS 02110
ATTORNEY DOCKET NUMBER:	2013064-0041
NAME OF SUBMITTER:	XIAODONG LI
SIGNATURE:	/Xiaodong Li/
DATE SIGNED:	10/06/2020
Total Attachments: 10	
source=2013064_0041_Assignment#page1.tif	

source=2013064_0041_Assignment#page2.tif
source=2013064_0041_Assignment#page3.tif
source=2013064_0041_Assignment#page4.tif
source=2013064_0041_Assignment#page5.tif
source=2013064_0041_Assignment#page6.tif
source=2013064_0041_Assignment#page7.tif
source=2013064_0041_Assignment#page8.tif
source=2013064_0041_Assignment#page9.tif
source=2013064_0041_Assignment#page10.tif

COMBINED JOINT ASSIGNMENT & DECLARATION

A. ASSIGNMENT

WHEREAS, each of the below-named inventors whose name and residence is set forth in the following Table 1:

Inventor Name	City, State
1. Anna Bunin	Rego Park, New York
2. Lawrence G. Iben	Bethany, Connecticut
3. Douglas Manion	Madison, Connecticut
4. David Adam Spiegel	Hamden, Connecticut
5. Matthew Ernest Welsch	New Haven, Connecticut

Table 1

hereby declares and agrees, on behalf of himself/herself and all of his/her successors and assigns that each is aware of the patent application(s) entitled:

CD16a BINDING AGENTS AND USES THEREOF; and

prepared for filing in the United States Patent and Trademark Office; or

identified by United States Application No. _____
filed in the United States Patent and Trademark Office on _____; and

identified by International Patent Application No. PCT/US19/12703
filed on January 8, 2019; and

and is also aware of the following priority applications:

Application No.	Filed
62/614,607	January 8, 2018

WHEREAS, **Kleo Pharmaceuticals, Inc.** (hereinafter "ASSIGNEE"), having a usual place of business at **25 Science Park, Suite 2D, 150 Munson Street, New Haven, Connecticut 06511**, desires to acquire or confirm an interest therein;

NOW, THEREFORE, to all whom it may concern be it known that, in consideration of agreements previously and duly entered into between the parties, and/or for other good and valuable consideration, the receipt of which is hereby acknowledged, each of us has sold, assigned, and transferred and/or do hereby sell, assign, and transfer unto said ASSIGNEE, its successors, assigns, and legal representatives, my entire right, title, and interest in and throughout the United States of America, its territories and all foreign countries, in and to any and all

inventions described in the patent application, and/or any priority applications noted above, including any right of priority thereto; and hereby confirm that my sale, assignment and transfer is and was effective at least as of the filing date of the patent application and/or priority application. Our sale, assignment and transfer applies to the above-referenced patent application, and to any application that is based in whole or in part on the patent application, including any divisional, continuing, substitute, renewal, reissue, reexamination and other applications, for example that claim priority to the patent application. Also, this sale, assignment and transfer pertains to any and all other rights arising under or pursuant to any and all international agreements, treaties, or laws relating to the protection of industrial property, including all rights of priority under the International Convention for the Protection of Industrial Property, and in and to any such patent(s) as may issue thereon including any and all original and reissued patents which have been or shall be issued in the United States and foreign countries; said inventions, applications, and patent(s) to be held and enjoyed by ASSIGNEE for its own use and for its successors, assigns and legal representatives, to the full end of the term for which said patent(s) may be granted as fully and entirely as the same would have been held by each of us had this sale, assignment and transfer not been made;

AND, each of us hereby acknowledges that this Assignment, being of our entire right, title, and interest in and to the inventions, carries with it the right in ASSIGNEE, by attorneys and agents of ASSIGNEE selection, to apply for and receive any and all patent(s) for said inventions in its own name;

AND, each of us hereby further agrees for ourselves and our executors and administrators to execute upon request any other lawful documents and likewise to perform any other lawful acts which may be deemed necessary to secure fully the patent(s) to ASSIGNEE, its successors, assignees, and legal representatives, but at its expense and charges, including the execution of application for patents in foreign countries, the execution of substitution, reissue, divisional or continuation applications, and the giving of testimony, preliminary statements, or other statements in any interference or other proceeding in which the inventions or any applications or patents directed to the inventions may be involved by communicating to the ASSIGNEE all facts we know relating to the inventions and their history, and generally by doing everything possible which ASSIGNEE shall consider desirable for aiding in securing and maintaining proper patent protection for the inventions and for vesting title in the inventions and all applications for patent and all patents on the inventions in ASSIGNEE;

AND, each of us further hereby authorizes ASSIGNEE or its attorneys or agents to insert the correct application number(s) and/or filing date(s) into this assignment document, if appropriate;

AND, each of us hereby appoints ASSIGNEE as our common agent for purposes of prosecuting international patent applications and any national patent applications for which such common agency is recognized;

AND, each of us hereby requests the Commissioner for Patents of the United States Patent and Trademark Office to issue any and all patent(s) as shall be granted upon said application or applications based thereon to ASSIGNEE, its successors, assigns, and legal representatives;

AND, each of us covenants with said ASSIGNEE that no assignment, grant, mortgage, license, or other agreement affecting the rights and property herein conveyed has been made to others by us, and that full right to convey the same as herein expressed is possessed by us.

B. DECLARATION (37 CFR 1.63)

As below named inventors, we hereby declare that:

This declaration is directed to the patent application entitled:

CD16A BINDING AGENTS AND USES THEREOF; and

attached hereto or prepared for filing in the United States Patent and Trademark Office; or

identified by United States Application No. _____
filed in the United States Patent and Trademark Office on _____; or

identified by International Patent Application No. PCT/US19/12703
filed on January 8, 2019.

The above-identified application was made or authorized to be made by us.

We believe that we are each an original joint inventor of a claimed invention in the application.

We hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. 1001 by fine or imprisonment of not more than five (5) years, or both.

We have reviewed and understand the contents of the application, including the claims and are aware of the duty to disclose to the United States Patent and Trademark Office all information known to be material to patentability as defined in 37 CFR 1.56.

Signature: *Anna Bunin*
Anna Bunin


Date: 02-05-19

Witness Signature: *Ada Vaill*


Witness Name (printed): Ada Vaill

Witness Signature: *Christian Vidal*

Witness Name (printed): Christian Vidal

Signature: 
Lawrence G. Iben


Date: 1/31/19

Witness Signature: 


Witness Name (printed): Christian Vidal

Witness Signature: 


Witness Name (printed): Maria Esposito

Signature:  _____
Douglas Marion


Date: Feb 5/2019

Witness Signature:  _____


Witness Name (printed): LUCA RASTECCI

Witness Signature:  _____

Witness Name (printed): BRIAN DOWD

Signature: 
David Adam Spiegel

Date: 2/5/19

Witness Signature: 


Witness Name (printed): ED Ntuli


Witness Signature: 

Witness Name (printed): BRIAN DOWD

Signature: 
Matthew Ernest Welsch

Date: 1-31-2019

Witness Signature: 
Witness Name (printed): LUCA RASTELLI

Witness Signature: 
Witness Name (printed): Roy FRIES

The undersigned (whose title is supplied below) is authorized to act on behalf of **Kleo
Pharmaceuticals, Inc.**

Signature:



Date:

Feb 5/2019

Name (printed):

Douglas Manion

Title (printed):

CEO